Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1996-10-22
Jordan, Charles T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514171, A61K 3156
Patent
active
055676960
ABSTRACT:
Systemic lupus erythematosus (SLE) is treated with dehydroepiandrosterone or its metabolite, sulfate ester, by itself or in combination with other therapies. Substantial improvement in SLE patients is observed during the course of treatment.
REFERENCES:
patent: 4628052 (1986-12-01), Peat
patent: 5001119 (1991-03-01), Schwartz et al.
Cottran, G. L., et al., "Altered Lipid Metabolism and Induction of Peroxisomal Activity in NZB/W Mice Fed a Diet Containing 0.45% Dehydroisoandrosterone (DHA)," The Journal of Cell Biology, Abstract No. 684, 107(6PT3):122A (1988).
Lucas, J. A., et al., "Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F.sub.1 Mice Fed Dehydroisoandrosterone," The Journal of Clinical Investigation 75(6):2091-2093 (1985).
Matsunaga, A., et al., "Effects of Dehydroeoiandrosterone (DHA) Administration on Macrophage Function and Spleen Cell Mitogenic Response in NZB/W Female Mice," The Faseb Journal, Abstract No. 4371, 2(5):A1048 (1988).
Matsunaga, A., et al., "Dehydroisoandrosterone Prevention of Autoimmune Disease in NZB/W F.sub.1 Mice: Lack of an /Effect on Associated Immunological Abnormalities," Biochimica et Biophysica Acta 992 (3):265-271 (1989).
Van Wollenhoven, R. P., et al., "Treatment of Systemic Lupus Erythematosus with Dehydropiandrosterone, A Pilot Study,"Arthritis and Rheumatism, Abstract No. 126, 35(9):S55 1992.
Van Wollenhoven, R. P., et al., "Treatment of Systemic Lupus Erythematosus with Dehydroepiandrosterone: Follow-Up from an Open-Label Clinical Trial," Abstract No. C241, Arthitis and Rheumatism 36(9):S228.
Van Wollenhoven, R. P., et al., "Treatment of Systemic Lupus Erythematosus with Dehydropiandrosterone: Interim Anaylsis of a Double-Blinded Randomized, Placebo-Controlled Clinical Trial," Abstract No. 322, Arthitis and Rheumatism 36(9):S92.
West et al., Ann. Internal Med 1988, 108, 703-706.
Engleman Edgar G.
McGuire James L.
Van Vollenhoven Ronald F.
Hardee John R.
Jordan Charles T.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Treatment of systemic lupus erythematosus with dehydroepiandrost does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of systemic lupus erythematosus with dehydroepiandrost, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of systemic lupus erythematosus with dehydroepiandrost will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2358798